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Abstract Fatigue is one of the most disabling symptoms in
multiple sclerosis (MS) patients. There is no or only weak
correlation between conventional magnetic resonance
imaging (MRI) parameters and level of fatigue. The aim of
this study was to investigate the relationship between pro-
gression of corpus callosum (CC) atrophy and fatigue in MS
patients. This was a cohort study in 70 patients with
relapsing form of MS (RRMS) and serial MRIs over a mean
follow-up of 4.8 years [67% female, mean age 42 ±
11 years, mean disease duration 9.7 ± 7.6 years, mean
Expanded Disability Status Scale (EDSS) 2.8 ± 1.6]. Fati-
gue was assessed by the Fatigue Severity Scale (FSS). CC
size was measured with the CC index (CCI). In total, 40% of
the patients suffered from fatigue (mean FSS score
5.3 ±1.1) and 60% patients had no fatigue (mean FSS score
of 2.1 ± 1). Patients with fatigue had higher EDSS scores
(p = 0.01) and CC atrophy was more pronounced in patients
with fatigue (-21.8 vs. -12.1%, p = 0.005). FSS correlated
with CCI change over time (r = -0.33; p = 0.009) and
EDSS (p = 0.008; r = 0.361). The association between
annualized CCI change and FSS was independent from
EDSS, disease duration, gender and age in a multivariate
linear regression analysis (p \ 0.001). Progression of CC
atrophy may play a role in the evolution of MS-related
fatigue.
Keywords Corpus callosum index  Corpus callosum
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Introduction
Multiple sclerosis associated fatigue is defined as a ‘‘sub-
jective lack of physical or mental energy that is perceived by
the individual or caregiver to interfere with usual and desired
activities’’ [7]. Fatigue is one of the most common symptoms
encountered in MS, leading to a severe level of disability and
impaired quality of life [13, 15, 20, 21]. Fatigue occurs in all
stages of the disease and usually does not correlate with
demographic or disease characteristics such as age, gender,
disability or disease severity [2, 3, 18, 22, 23, 28, 40]. The
pathophysiology of MS-related fatigue is not fully under-
stood and seems to be multifactorial [7]. Functional imaging
studies [12, 34, 35] have demonstrated an abnormal
recruitment of cortical and subcortical networks in MS
patients with fatigue supporting the theory of a central origin.
It has been suggested that diffuse wide-spread axonal loss in
MS patients might play a role in the pathogenesis of fatigue.
However, structural magnetic resonance imaging (MRI)
studies have provided conflicting results concerning the
relation between fatigue severity and brain pathology [4].
Since the corpus callosum (CC) is the largest and function-
ally most important interhemispheric connection bundle,
commonly affected in MS, we hypothesized an association
between CC atrophy and fatigue.
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Patients and methods
This is an exploratory observational MS cohort study with
the analysis of CC size on brain MRI as measured at two
timepoints, at diagnosis and at time of study. The study was
approved by the local ethic committee of the Cantonal
Hospital St. Gallen, Switzerland.
Patients
We assessed MRI and fatigue in 97 consecutive patients
attending our outpatient clinic and fulfilling the following
inclusion criteria: age between 18 and 60 years, diagnosis
of a relapsing form of MS according to McDonald criteria
(revised version 2005 [31]) and an actual cranial MRI scan
(within 3 months before visit). Exclusion criteria are given
in Table 1.
We excluded four patients due to co-medication sup-
posed to have an effect on fatigue, including one patient
with zopiclone, one patient with mirtazapine and two
patients with amitryptiline. Moreover, we excluded one
patient with pure spinal manifestation of disease, and 22
patients because of depressive symptoms. Thus, this anal-
ysis included data of 70 MS patients. Disease duration was
defined as time since first manifestation of MS. Relapses
were defined as the development of new or recurrent
neurological symptoms not associated with fever or
infection lasting at least 24 h confirmed by a Swiss or
German board-certified neurologist. EDSS and fatigue
were assessed with a maximum time distance of 1 month.
Fatigue assessment
Fatigue was assessed in all patients using the Fatigue
Severity Scale (FSS; see appendix). FSS is a 9-item mea-
sure. The patients had to rate the degree of agreement of a
given statement on a 7-point ordinal scale ranging from 1
(strongly disagree) to 7 (strongly agree). Scores were cal-
culated by deriving an arithmetic mean. FSS scores of C4
where suggested to be indicative of ‘‘fatigue’’ whereas
FSS \4 characterizes ‘‘no fatigue’’ [21]. Depressive
symptoms were assessed by Beck’s Depression Inventory
[5].
MRI analysis
All MRI scans were performed in the radiological institute
of the Cantonal Hospital St. Gallen (1.5 Tesla Sigma
Magnetom Scanner, Siemens AG, Germany) including an
axial pre- and post-Gadolinium T1 weighted, sagittal T1
weighted, sagittal fluid attenuated inversion recovery
sequence (FLAIR), axial T2 weighted and axial FLAIR
sequences. The first MRI represented the MRI at diagnosis.
The last MRI was performed within 3 months before fati-
gue assessment. All MRI scans were analysed by the same
examiner (OY). For CC measurement we used the CC
index (CCI) on Picture Archiving Communicating System
and if on-screen MRIs are not available on hardcopies. CCI
is an established linear measurement technique, published
elsewhere (Fig. 1) [11, 41].
Higher CCI values indicate a higher CC volume. OY was
blinded to the clinical data of the patients. Forty-seven MRIs
(33.6%) were evaluated by a second rater (SG), on-screen
blinded to the results of OY and clinical data. The concor-
dance rate was 0.91. In 38 patients (54.3%) actual MRI were
both available on-screen and hardcopies. In these patients,
hardcopy MRIs were additionally evaluated by SG who
blinded to the results from on-screen measurement with a
Table 1 Exclusion criteria of the study
Exclusion criteria
Progressive forms of MS
Concomittant brain pathology
Neuromyelitis optica
Pure spinal manifestation of disease
Clinical relapse within the last 30 days
Corticosteroid treatment within 12 weeks prior to fatigue
assessment
Depressive symptoms (Beck’s depression inventory C15 points [5]
History of substance abuse
Any other relevant medical disease
Clinical signs of infection within the last 3 weeks
Medication which could affect fatigue within the last 8 weeks
Fig. 1 Calculation of corpus callosum index (CCI). CCI is calculated
as (aa0 ? bb0 ? cc0)/ab0. Lower CCI values indicate a lower CC
volume [11]
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concordance rate of 0.88. T2 and T1 lesion load and contrast
enhancement were determined by Swiss or German board-
certified radiologists. The T2 lesion load was dichotomized
as\9 T2 lesions or C9 T2 lesions. T1 lesions and contrast
enhancing lesions were categorized as present or absent.
Statistical analysis
Demographic data are presented as mean, standard deviation
and 95% confidence interval (CI). Curtosis was calculated
for continued variables. We used the Mann–Whitney U test
for independent samples for comparison of continued vari-
ables and applied the non-parametric rank correlation
analysis Spearman-Rho. The significance level was cor-
rected for multiple testings by Bonferroni (adjusted p value:
0.05/5 = 0.01). We used a multivariate linear regression
analysis (backward directed regression model) to analyse
the interdependence of potential confounding variables. FSS
was set as continuous outcome parameter. Clinically
meaningful confounders included disease duration, gender,
EDSS, age, CCI and annualized CCI change since diagnosis
of MS. We used SPSS (MAC version 18; SPSS, Chicago, IL)
for all statistical analysis.
Results
Mean FSS in all patients was 3.37 ± 1.88. Forty percent of
the patients (n = 28) had fatigue according to the defini-
tion (mean FSS score of 5.27 ± 1.1). Sixty percent of the
patients (n = 42) had no fatigue (mean FSS score of
2.1 ± 1.0). Patients’ demographic and clinical character-
istics in total and group-wise are given in Table 2.
Group-wise univariate comparisons of baseline
characteristics
Most of the patients’ characteristics were similar in both
groups including gender, age, disease duration, annualized
relapse and steroid treatment rate, treatment with disease
Table 2 Patient’s characteristics
Characteristics Total FSS \ 4 FSS C 4 p Curtosis
n (%) 70 42 (60) 28 (40)
Age 41.8 ± 10.9 (39;44.6) 40.4 ± 10.5 (36.8;44) 43.7 – 11.4 (39;48.4) 0.26 -0.42
Gender (%) 0.77 n/a
Female 61 (67.1) 37 (88.1) 24 (85.7)
FSS 3.37 ± 1.88 (2.92; 3.82) 2.1 ± 1.04 (1.78; 2.43) 5.27 ± 1.09 (4.85; 5.69) \0.001* -0.61
EDSS 2.8 ± 1.6 (2.3;3.2) 2.4 ± 1.7 (1.8;3.0) 3.3 ± 1.2 (2.8;3.9) 0.01* -0.04
Disease duration in years 9.7 ± 7.6 (7.8;11.6) 9 ± 6.8 (6.7;11.2) 10.7 ± 8.6 (7.3;14.2) 0.36 0.14
ARR 1.1 ± 1.7 (0.7;1.6) 0.84 ± 0.65 (0.6;1.1) 1.6 ± 2.5 (0.4;2.7) 0.44 29.9
ASR 0.5 ± 1.1 (0.2;0.8) 0.4 ± 0.4 (0.2;0.5) 0.7 ± 1.6 (0.02;1.3) 0.76 37.6
DMT (%) 0.08 n/a
Never 9 (12.9) 3 (7.1) 6 (21.4)
Yes 61 (87.1) 39 (92.9) 22 (78.6)
DMT duration in years 4.1 ± 3.5 (3.2;5.0) 4.1 ± 3.2 (3;5.2) 4.2 ± 3.8 (2.6;5.7) 0.76 -0.42
Lesion load on T2w brain MRI 0.83 n/a
\9 lesions 19 (27.1) 11 (26.2) 8 (28.6)
C9 lesions 51 (72.9) 31 (73.8) 20 (71.4)
Black holes on T1w MRI 0.66 n/a
No 18 (25.7) 10 (23.8) 8 (28.6)
Yes 52 (74.3) 32 (76.2) 20 (71.4)
Contrast enhancing lesions on T1w MRI 0.22 n/a
No 64 (91.4) 37 (88.1) 27 (96.4)
Yes 6 (8.6) 5 (11.9) 1 (3.6)
Continued parameters were compared with Mann–Whitney U test and dichotomized parameters with the Chi Square test. Significance level
(p value) = 0.05. Values are given in mean and 95% confidence intervals
ARR annualized relapse rate since diagnosis of MS, ASR annualized steroid pulse therapy since diagnosis, CI confidence interval, DMT disease
modifying treatment, EDSS Expanded Disability Status Scale, FSS Fatigue Severity Scale, n/a not available, T1w/T2w MRI T1/T2 weighted
magnetic resonance images
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modifying drugs and conventional MRI characteristics.
However, patients with fatigue had higher EDSS scores
(p = 0.01; Table 2).
CC atrophy in patients with and without fatigue
In all patients, mean CCI at diagnosis was 0.36
and decreased to 0.31 in the last MRI (annual CCI decrease
-0.8%). CCI values on first and last MRI with refer to time
since first manifestation of MS are given in Fig. 2.
CCI at diagnosis and CCI on last MRI were not sig-
nificantly different in both groups but CCI change over
mean of 4.8 years was more pronounced in patients with
fatigue: -21.8% compared to those without -12.1%
(p = 0.005; Fig. 3a). This difference remains significant
after correction for the time between first and last MRIs:
annual CCI decrease was -1.1% in patients with fatigue
compared to 0.6% in patients without (p = 0.02). Results
of CCI assessment are given in Table 3.
Correlation analysis between CCI and fatigue
CCI change over time correlated with FSS at last MRI
(q = -0.333; p = 0.009; Fig. 3b), EDSS (q = -0.367;
p = 0.007) and disease duration (q = -0.378; p = 0.003).
Moreover, EDSS correlated with FSS at study time-point
(q = 0.361; p = 0.008) and with disease duration
(q = 0.489; p \ 0.001). FSS did not correlate with disease
duration (q = 0.121; p = 0.34).
Linear regression model
Multivariate linear regression analysis using FSS as the
dependent continuous variable and disease duration, gen-
der, EDSS, age, last CCI and annualized CCI (aCCI)
change from first to last MRI as co-variates revealed both
EDSS and annualized CCI change as independent factors
associated with FSS (p value of the regression
model = 0.006; adjusted Nagelkerkes’ R square = 0.23;
Table 4).
Discussion
The main finding of our study is that progression of CC
atrophy over a mean of 5 years after diagnosis is associated
with the occurrence and severity of MS-related fatigue.
In MS patients, CC atrophy is a common finding
[17, 38] and correlates with whole brain atrophy [38].
Among others, we recently showed that CC atrophy cor-
relates with progression of disability in MS [29, 36, 41]. In
recent decades, several studies could demonstrate cognitive
dysfunction in patients with CC abnormalities not only due to
MS [11, 26, 32]. In our study, CC atrophied by a mean of
approximately 0.8% per year which was in the range of studies
using other methods, such as brain parenchymal fraction
method (0.5–1.8% annual brain volume loss [1, 6, 16, 19]).
Fig. 2 Corpus callosum index (CCI) on first and last MRI with refer
to time since first manifestation of MS
Fig. 3 a Box-and-whisker
diagram of corpus callosum
index (CCI) change from
baseline (1.0) in fatigued and
non-fatigued MS patients.
Fatigue is associated with a
more pronounced CCI decrease
within the last 5 years (88 vs.
79%, mean values; Mann–
Whitney U test; p = 0.005).
b Scatter plot of annualized CCI
change and fatigue severity
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Like in our study, Martola et al. [25] did not find any
association between midsagittal CC area and gender, age
and disease duration investigating 37 MS patients. That
fatigue severity is independent from disease duration is
well-known. There are studies reporting a fatigue preva-
lence of more than 50% in patients with early forms of
MS [37]. The association between progression of CC
atrophy and fatigue severity in our study was independent
from disability. The common scientific viewpoint is that
EDSS does not correlate with fatigue despite of some
studies which found a weak association [14, 30]. How-
ever, the weak correlation between EDSS and fatigue in
our study is probably due to patient selection. In the last
decade several studies were conducted investigating the
association between fatigue and brain pathology. Most of
these studies are designed cross-sectional and found,
similar to our results, no correlation between fatigue
severity and conventional MRI parameters such as the
extent and location of T2 lesions [2, 8, 9, 27, 37, 39, 40],
the occurrence of contrast enhancing lesions [23] or brain
atrophy [2, 40]. Only one study could demonstrate higher
T2 lesion burden in 15 non-disabled MS patients with
fatigue compared to 15 patients without [10] with a cor-
relation coefficient of 0.5 (p \ 0.005). Recently, a study
found in 24 patients with RRMS and 14 healthy controls
reduced grey matter volume in the frontal lobe [33].
Results from our regression model suggest that pro-
gression of corpus callosum atrophy contributes indepen-
dently to fatigue severity in MS patients. Similar findings
were found in another study investigating the association
between progression of brain atrophy and fatigue severity:
Marrie et al. [24] investigated 134 MS patients and found
that an increase of fatigue correlated with changes of brain
volume over 8 years while short term changes in brain
volume and fatigue were not correlated. In contrast to our
study, fatigue was measured by the Sickness Impact Profile
Sleep and Rest Scale. They also found that the association
between progression of brain atrophy and fatigue was
independent from conventional MRI parameters such as
contrast enhancement and T2 lesion load.
Table 3 Results from corpus callosum index (CCI) assessment
Total FSS \ 4 FSS C 4 p Curtosis
n (%) 70 42 (60) 28 (40)
Observation time since
MS diagnosis in years
4.8 ± 4 (3.7;5.9) 4.4 ± 3.9 (3;5.8) 5.4 ± 4.2 (3.5;7.3) 0.46 1.2
CCI at time of MS diagnosis 0.36 ± 0.07 (0.34;0.38) 0.35 ± 0.07 (0.33;0.37) 0.38 ± 0.06 (0.35;0.4) 0.18 0.58
Actual CCI 0.31 ± 0.07 (0.29;0.32) 0.31 ± 0.08 (0.29;0.34) 0.29 ± 0.05 (0.27;0.32) 0.11 -0.72
Last CCI versus first CCI in % 84 ± 14.8 (80.2;84.8) 87.9 ± 14.9 (82.6;93.2) 79.2 ± 13.4 (73.9;84.5) 0.005** 0.28
Annual CCI change
in % of first CCI
-0.8 ± 0.9 (-1;-0.55) -0.55 ± 0.96 (-0.89;-0.2) -1.1 ± 0.8 (-1.4;-0.8) 0.02* 0.81
CCI at diagnosis and time of study were not decreased in patients with fatigue compared to those without but annual CCI change over the last
5 years (mean value) was significantly lower in the fatigue group. Values in parentheses represent 95% confidence interval
CCI corpus callosum index, FSS Fatigue Severity Scale, p significance level
Table 4 Linear regression analysis using FSS as the dependent variable
Model Non standardized coefficients Standardized
coefficient beta
T p
Regression coefficient beta Standard error
Constant 0.788 1.881 0.419 0.677
Disease duration 0.006 0.042 0.025 0.154 0.878
Gender -1.386 0.72 -2.44 -1.927 0.06
EDSS 0.368 0.164 0.32 2.244 0.03*
Age 0.04 0.024 0.239 1.662 0.103
CCI 5.89 3.561 0.235 1.654 0.105
aCCI change -81.671 26.933 -0.428 -3.032 0.004*
Both EDSS and aCCI change over time were independently associated with FSS (p value of the model 0.006; adjusted Nagelkerkes’ R square
0.227)
aCCI change annualized CCI change, CCI corpus callosum index, EDSS Expanded Disability Status Scale Score, FSS Fatigue Severity Scale
Score
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Strengths and limitations
This is an observational and explorative clinical study with
retrospective assessment of CC size. However, the rater
were blinded to clinical characteristics. The measurement
technique is valid and reliable [11, 41]. It has been shown
to correlate with brain parenchymal fraction [11]. The
concordance rate between two independent raters and
between measurement on screen and hardcopies was
excellent and similar to results published recently [41]. An
advantage of this study is the inclusion of a large com-
munity-based patient population, close timing of MRI and
fatigue assessment and careful selection criteria to insure
the measurement of MS-related fatigue. We excluded
patients with progressive forms of MS to avoid a hetero-
geneous study population with a small number of patients
in one group. We used a validated depression scale to
exclude patients with depressive symptoms [5] and used
FSS because of its high reliability, validity and internal
consistency. FSS is the most widely used fatigue scale in
cross-sectional and longitudinal MS studies [22]; initial
studies of the FSS to assess test–retest reliability of the FSS
in MS provided a correlation coefficient of 0.84. The
internal consistency of the FSS using Cronbach in MS was
0.81 [21]. However, FSS remains a subjective parameter.
Another disadvantage of this study is the relatively
imprecise assessment of disease burden on MRI. Further
studies should include exact volumetric measurements of
MS lesions.
Conclusions
Progression of CC atrophy over time seems to be an
independent risk factor of MS related fatigue. However,
our multivariate regression model could explain only
about one-fourth of the variance of fatigue severity.
MS-related fatigue remains largely unpredictable sug-
gesting other important confounder not yet identified.
There is high need of more objective assessment tools
for fatigue. Our results should be reproduced by further
studies using innovative quantitative MR-based tech-
niques such as voxel-based morphometry or diffusion
tensor imaging.
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